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Africa is the only continent where chronic hepatitis B virus (HBV) 
infection remains hyperendemic with exposure, as measured by 
anti-HBc-positivity, of greater than 85% in western Africa, 65 - 85% 
in eastern Africa and 35 - 75% in southern Africa.[1] A quarter of 
the world’s 257 million chronic carriers of HBV reside in Africa and 
this figure most probably underestimates the true carrier rate due to 
underreporting and a lack of extensive surveillance. As a consequence 
of the high chronic HBV carrier rate there is a correspondingly high 
annual incidence of hepatocellular carcinoma (HCC) of 14.8 per 
100 000 in males and 6.2 per 100 000 in females,[2] ranking second 
and fifth of the leading cancer-associated deaths for men and 
women, respectively.[3] In western Africa, HCC is the most commonly 
diagnosed cancer in males, with the highest annual fatality ratio for 
any human tumour of 0.93.[4] Chronic HBV infection is the primary 
aetiological risk factor for the development of HCC in Africans, with 
two-thirds of children and up to 80% of adults being carriers of the 
hepatitis B surface antigen (HBsAg).[5,6] Apart from chronic HBV 
infection, other co-carcinogens contributing to the development of 
HCC in Africa include dietary iron overload[7] and aflatoxin B1.[8]
Genotypes and subgenotypes of HBV
Although HBV has a DNA genome, it replicates via an RNA 
intermediate, through the process of reverse transcription catalysed 
by a viral polymerase that lacks proofreading ability. Sequence 
heterogeneity is therefore a feature of the virus. Currently, at least 
9 genotypes and over 35 subgenotypes of HBV are recognised 
globally[9] with distinct geographical distributions. The genotypes 
prevalent in south-east Asia differ from those in Africa.[9,10] 
Geographical distribution of HBV 
genotypes in Africa
Africa has a high diversity of genotypes and subgenotypes displaying 
distinct geographical distributions. Genotype A is found mainly 
in south-eastern Africa, genotype E in western and central Africa 
and genotype D prevails in northern Africa.[1] We have identified a 
unique segment of genotype A, known as subgenotype A1,[11,12] which 
is the prevalent subgenotype of A found in Africa. Subgenotype A2 
predominates outside Africa[13] and genotype E, a predominantly 
African strain, is endemic in western and central Africa and has low 
genetic diversity reflecting emergence less than 200 years ago.[14] In 
contrast to subgenotype A1 that was dispersed by the slave trade,[13] 
genotype E is rarely found outside Africa, except in individuals of 
African descent, further supporting a recent emergence following the 
forced migrations of slaves.
This paper serves to present the outcomes of our research on 
subgenotype A1 and genotype E, characterising the unique molecular 
features of these African strains, which most likely influence the 
natural history and the subsequent clinical manifestations of chronic 
HBV infection in Africa.[15] The research was carried out in South 
Africa (SA), Zimbabwe, Kenya, Namibia, Nigeria and Sudan. The 
geographic distribution and prevalence of the HBV genotypes in 
these countries are shown in Fig. 1. Genotype A predominates in 
SA,[11,12,16,17] Zimbabwe[18] and Kenya[19] and genotype E is common 
in Namibia[20] and Nigeria.[21] In the Sudan, three genotypes are 
described, genotypes A, D and E, and the lack of a predominant 
genotype most likely reflects Sudan’s unique geographical location 
and the flux of peoples across its borders.[22-24] 
Genotype distribution in relation to 
clinical manifestation of infection
The predominance of genotype A and subgenotype A1 in SA, 
Zimbabwe and Kenya was found in blood donors, asymptomatic 
carriers of HBV and patients with cirrhosis and HCC.[11,18,19] In SA 
HBV/HIV co-infected patients, 97% of the HBV isolates belong 
to subgenotype A1 and 3% to subgenotype D3.[16] In Sudan, the 
genotype distribution varies according to the clinical manifestation 
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of the chronic HBV infection, with genotype E predominating in 
asymptomatic carriers and blood donors,[23,24] whereas genotype D 
is found in those carriers with liver disease, including those patients 
with HCC.[23] An opportunity to compare genotype D and E in a 
similar group of Sudanese[23] revealed that patients infected with 
genotype E had a higher frequency of HBeAg-positivity and higher 
viral loads compared with those patients with HBV that were infected 
with genotype D.[23] In a subsequent study, HBV/HIV co-infected 
patients had a higher frequency of genotype D/E, recombinant 
genotype A and intragroup divergence of genotype E compared with 
HBV mono-infected individuals.[22]
Subgenotype A1
Africa is likely the origin of subgenotype A1, which spread globally 
to Asia and Latin America at approximately the same time.[13] 
Our phylogeographic analysis including the unexpected finding 
of co-clustering of Somalian and Latin American strains and the 
dispersal of subgenotype A1 from India to Haiti, correlates well with 
the historical evidence, which implicates trade and slave routes of 
dispersal of subgenotype A1, between the 9th and the 19th centuries 
AD.[13] 
Carriers of subgenotype A1 have characteristic clinical features, 
which includes lower HBV DNA levels in both the HBeAg-positive 
and HBeAg-negative phases. In a case-control study, HBV DNA 
levels in HBeAg-positive and HBeAg-negative subgenotype A1 
carriers were significantly lower than those of subgenotype A2 or 
genotype D carriers.[25] In HBV-infected individuals younger than 30 
years of age the frequency of HBeAg-positivity is lower in those with 
subgenotype A1 compared with those infected with subgenotypes 
A2 or D.[25] Perinatal transmission occurs at a relatively high 
rate in HBeAg-positive mothers compared with HBeAg-negative 
mothers,[26] and since women of child-bearing age in Africa are 
usually younger than 30 years of age, and more often HBeAg-
negative, perinatal transmission of subgenotype A1 is uncommon 
and vertical transmission is not an efficient mode of transfer. The 
most frequent mode of transmission of subgenotype A1 is horizontal 
and occurs via intrafamilial and to a lesser extent interfamilial route. 
Although the exact mode of horizontal transmission has not been 
elucidated, environmental, behavioural and cultural factors are 
likely to be contributary. Cultural practices such as scarification and 
tattooing and iatrogenic procedures including indiscriminate use of 
injections or non-sterilised syringes have all been implicated. In a 
study carried out with the South African National Blood Transfusion 
Service, we were able to show that subgenotype A1 can be transmitted 
horizontally by blood transfusion at very low viral levels (of 32 HBV 
DNA copies per 20 mL of plasma at a rate of 0.34 per million).[27] 
Furthermore, HBV could not be detected in blood donors even 
though individual donor nucleic acid testing was performed.[27]
By comparing the distribution of the genotypes in 111 
southern African patients with HCC and an equivalent number of 
asymptomatic HBV carriers (ASCs), subgenotype A1 was shown 
to have an increased hepatocarcinogenetic potential compared 
with subgenotype A2 and genotype D (relative risk of 4.5; 
95% confidence interval 1.86 - 10.90).[17] Moreover, the mean age 
of the HCC patients infected with genotype A (predominantly 
subgenotype A1) was 6.5 years younger than those infected with 
genotype non-A (p<0.05).[17] This confirms our earlier observation 
that the proportion of genotype A precore sequences (majority 
subgenotype A1) in HCC patients was significantly higher than 
those in ASCs.[28] All precore sequences derived from tumorous 
and non-tumorous liver tissue samples had 1888A - a characteristic 
of subgenotype A1.[28]
By measuring the crude geometric means of M30, a systemic marker 
for apoptosis, SA chronic HBV carriers infected with subgenotype A1 
had significantly higher levels of liver inflammation compared with 
patients infected with genotype D. Furthermore, patients with HCC 
also had significantly higher levels of M30 compared with ASCs.[29]
The characterisation of subgenotype A1 may help us understand 
the mechanisms of tumorigenesis and may indeed help develop 
targets for both antiviral and anti-tumour therapies. In order to 
explain the high frequency of HBeAg-negativity and tumorigenic 
potential of subgenotype A1 our research focused on two aspects: 
functional and molecular characterisation.
Functional characterisation of 
subgenotype A1 using in vitro models
For this purpose, replication-competent plasmids of HBV 
subgenotypes A1, A2 and D3 were constructed with authentic 
endogenous promoters.[30] Following transfection of Huh7 cells, 
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Fig. 1. The genotype distribution of HBV in Africa derived from our 
studies. The data were obtained by sequencing as follows: South Africa (23 
full-length sequences of HBV isolates from asymptomatic carriers of the 
virus (ASCs) and fulminant (FH)/acute hepatitis (AH) cases);(11) Namibia 
(6 full-length HBV genomes from chronic hepatitis (CH) patients);(20) 
Zimbabwe (27 preS1/preS2/S sequences (nt 2854–835 numbering 
according to GenBank accession #AY233274) and 2 complete genomes 
from blood donors);(18,21) Kenya (40 preS1/preS2/S sequences (nt 2854–
835) from hepatocellular carcinoma (HCC), cirrhotic (CR), CH patients 
and ASCs);(19) Nigeria (17 complete S/partial polymerase sequences (2535-
1099 from EcoR1) of hepatitis B virus (HBV) isolated from HBV/HIV-
co-infected individuals)(21) and Sudan (53 preS1/preS2/S sequences (nt 
2854–835) from HCC, CR, CH, AH patients and ASCs and HBV/HIV 
co-infected individuals).(22,23) Insert shows an unrooted phylogenetic tree 
of 34 full genomes of HBV sequenced in our studies and established using 
neighbour-joining. Each sequence is designated by a GenBank accession 
number and the country of origin. 
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subgenotype A1 plasmids replicated at lower levels than subgenotype 
A2,[30,31] which reflects the difference observed in patients infected with 
different subgenotypes.[25] This is consistent with the observations of 
others in transfection experiments[31] leading to the intracellular 
accumulation of replicative intermediates and HBcAg,[30] which may 
play a role in inducing liver damage.[31] This has been implicated 
in hepatocarcinogenesis and is supported by in vitro experiments, 
which demonstrated that Huh7 cells transfected with subgenotype 
A1 showed greater endoplasmic reticulum (ER) stress compared 
with cells tranfected with subgenotypes A2 and D3. Moreover, there 
was an earlier and prolonged activation of the unfolded protein 
response (UPR) as seen by the high activity of three ER-localised 
transmembrane transducers: double-stranded RNA-dependent 
protein kinase-like ER kinase, activating transcription factor 6 and 
inositol-requiring enzyme 1. In addition, cells transfected with 
subgenotype A1 have the highest level of apoptosis.[32]
Basic core promoter (BCP)/precore mutations and 
variations of subgenotype A1 
Subgenotype A1 develops different mutations in the BCP/precore 
region when compared with subgenotypes A2 and D3.[33,34] There are 
three levels at which these mutations/variations can affect HBeAg 
expression.
Firstly, at the transcriptional level, the BCP mutations 1762T1764A 
have an affect on the transcription of the precore mRNA, which 
results in the reduction of HBeAg expression. The double mutation 
is highly prevalent in HBV isolates from patients with HCC. Our 
earlier studies showed that 66% of patients with HCC had mutations 
1762T1764A in the BCP compared with only 11% of ASCs.[35] This 
observation has been confirmed by numerous subsequent studies 
regardless of the HBV genotype. The double BCP mutation has been 
shown to be an independent risk factor for the development of HCC 
in genotypes B and C.[36] 
Secondly, variations at positions 1809 - 1812 from the EcoRI site 
in the Kozak sequence of the precore/core open reading frame, 
characteristic of subgenotype A1, have an effect on HBeAg expression 
at the translational level.[37] Instead of 1809GCAC1812, which is present 
in subgenotypes A2 and D3, subgenotype A1 has 1809TCAT1812.[34] This 
variation converts the Kozak region from an optimal to a suboptimal 
translational context[11] and results in the decreased translation of 
HBeAg by a ribosomal leaky scanning mechanism.[37] Compared 
with subgenotypes A2 and D3, transfection with subgenotype A1 
leads to a lower expression of the precore/core precursor in the 
secretory pathway and a higher co-localisation in the nucleus.[32] The 
reduction in HBeAg levels is comparable with that observed in the 
presence of 1762T1764A and when occurring together, the Kozak and 
BCP 1762T1764A mutations reduce HBeAg expression in an additive 
manner.[37] An additional mutation at position 1810 severely impairs 
HBeAg expression.[37] The reduction in HBeAg expression may 
contribute to the early loss of HBeAg in individuals infected with 
subgenotype A1.[25]
Thirdly, a G to T transversion at position 1862 in the precore region 
occurs frequently in subgenotype A1, and is more common in HBeAg-
negative than in HBeAg-positive South African carriers,[28,38] which 
affects HBeAg expression at the post-translational level. This mutation 
results in a valine to phenylalanine substitution in the –3 position 
of the signal peptide cleavage site at position 19 of the precursor 
protein. Phenylalanine is an aromatic amino acid which interferes with 
signal peptide cleavage.[39] When this mutation was introduced into a 
genotype D plasmid driven by a cytomegalovirus promoter, it resulted 
in a 54% reduction in the secretion of HBeAg relative to the wild-type 
and to the subsequent formation of aggresomes.[40] In the context 
of a subgenotype A1 backbone, this mutation diminishes HBeAg 
expression but at a lower degree (22%). The mutant was found to lead 
to the accumulation of the HBeAg precursor protein in the ER and 
ER-Golgi intermediate compartment (ERGIC) and this accumulation 
resulted in an earlier activation of the three UPR pathways. It did not 
however lead to an increase in apoptosis.[32] HBV strains with G1862T 
have been isolated from sites of HCC tumors but not from adjacent 
non-tumorous liver tissue.[28] 
As a result patients, infected with subgenotype A1 with 
characteristic suboptimal Kozak sequence preceding the precore 
start codon, together with 1762T1764A and 1862T mutants, have 
severely diminished levels of HBeAg. The reduction or absence of 
HBeAg in the serum results in an immune response driven directly 
to hepatocytes, which together with the increased ER stress, results in 
liver damage and thus contributes to the higher hepatocarcinogenic 
potential of the A1 subgenotype.[34] 
In addition to the characteristic 1809TCAT1812 in the precore 
Kozak sequence, subgenotype A1 has 1888A, differentiating it from 
subgenotype A2 and other genotypes that have 1888G, results in a 
positive regression coefficient for subgenotype A1 and a negative one 
for subgenotype A2.[41] This transition introduces an out-of-frame 
AUG, creating an overlapping upstream open reading frame (uORF), 
terminating five nucleotides downstream from the core AUG. 
This uORF can potentially be translated into a seven amino acid 
peptide.  When  Huh7 cells were transfected with reporter plasmids[42] 
and the introduction of uORF resulted in an 18.75% reduction in 
core gene expression. When the suboptimal Kozak sequence of the 
1888 AUG was replaced with an optimal one, the reduction was 
enhanced (64.84%). By increasing the distance between the stop 
of the overlapping uORF and the core AUG by a minimum of 15 
nucleotides, core/GFP expression was almost doubled, indicating 
that stalling of ribosomes at the stop of the uORF may interfere with 
initiation at the core AUG through steric hindrance. Our findings 
indicate that the G1888A. mutation interferes with initiation at the 
downstream 1901 core AUG decreasing core protein translation. 
This may account for the relatively low viral loads seen in individuals 
infected with subgenotype A1.[42] 
Pre-S1/pre-S2/S deletion mutants in subgenotype A1
Eighteen SA HCC patients infected with subgenotype A1 were 
studied and 72% had HBV pre-S gene deletions. The most prevalent 
deletions were deletions across pre-S1/pre-S2, pre-S2 initiation codon 
mutations with internal deletions and S gene nonsense mutations.[43] 
Similar observations were made in HBV strains isolated from 
Indian HCC patients infected with subgenotype A1.[44] The pre-S2 
start codonM1T/I mutation was unique to genotype A strains and 
occurred at a statistically significantly higher frequency in isolates 
from patients with HCC.[44] Both experimental and clinical studies 
provide strong evidence for a link between these mutants and the 
pathogenesis of HCC. A meta-analysis of 43 studies that evaluated 
approximately 11 500 HBV-infected patients, showed that infection 
with pre-S deletion mutants is associated with a 3.77-fold increased 
risk of HCC.[45] Moreover, a prospective study revealed a predictive 
value of pre-S mutants in the development of HCC and pro-
oncogenic role of mutated envelope proteins.[46]
Although most of our work has focused on subgenotype A1, 
we have now initiated work on the molecular and functional 
characterisation of genotype E, which is an African strain with 
unique characteristics.
Genotype E
Genotype E has the unique serological subtype ayw4, a genomic 
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length of 3 212 nucleotides and can be differentiated from genotypes 
A to D, F, H and I, by a 3-nucleotide deletion in the pre-S1 region.[9] 
In addition, we have identified another unique feature of genotype 
E strains: the introduction of another start codon Met83 in the pre-
S1 region that may result in the translation of an elongated middle 
hepatitis B surface protein (MHBs).[20]
Western Africa represents the only major region in the world 
where HBV is still hyperendemic and the predominant genotype 
prevailing there is genotype E.[1] In Sudan, where both genotypes 
D and E are prevalent, it was possible to compare the clinical 
features of patients infected with these two genotypes. Patients 
with liver disease[23] and blood donors[24] had viral loads that were 
significantly higher in genotype E-infected patients compared 
withgenotype D-infected patients and furthermore patients 
infected with with genotype E were more likely to be HBeAg-
positive. The G1896A mutation accounts for the HBeAg-negativity 
in non-A genotypes and this mutation introduces a stop-codon 
in the HBeAg precursor, which leads to its truncation and to the 
non-expression of the mature HBeAg.[47] The region that codes 
for HBeAg overlaps pregenomic RNA, which requires to be folded 
into a secondary structure known as the encapsidation signal (ε). 
In genotype A, there is an 1858C, which prevents the development 
of 1896A since this would disrupt Watson-Crick C-G base pair and 
lead to the destabilisation of ε. On the other hand, in genotypes 
such as D and E, which have an 1858T, the G1896A mutation results 
in the stabilisation of ε with the conversion of a wobble to a stable 
Watson-Crick T-A pair. Presently it is unclear why G1896A is 
positively associated with genotype D and negatively associated 
with genotype E,[41] even though both genotypes have 1858T. This 
lack of association of G1896A with genotype E might explain the 
high frequency of HBeAg-positivity in individuals infected with 
genotype E. Moreover, a high frequency of HBeAg-positivity in 
mothers infected with genotype E would account for significant 
perinatal transmission[26] and possibly explain the high prevalence 
and geographical location in western Africa. 
Since HBeAg is small it is able to cross the placenta easily and 
elicits HBe/HBcAg-specific T helper cell tolerance in utero.[48] As 
a result, babies born to HBeAg-positive mothers in Africa with 
genotype E have high chronicity rates compared with those born to 
HBeAg-negative mothers with genotype E.[48,49]
The higher HBeAg-positivity described in individuals infected 
with genotype E might confer tolerance and a milder clinical 
manifestation of the disease than genotype D, where HBeAg-
positivity was lower. This could explain the higher prevalence of 
genotype E in Sudanese blood donors,[24] whereas genotype D is 
more prevalent in those patients with liver disease.[23] 
In the Sudan, although pre-S deletion mutants were found in 
both genotype D and genotype E they were only found in HCC 
patients infected with genotype E. In genotype D patients they were 
found in ASC, cirrhotics and chronic hepatitis patients[23] and the 
significance of this is unknown. 
Genotypes in HBV/HIV co-infection and occult HBV 
infection
Of the 36 million adults and children living with HIV globally, 27 
million reside in sub-Saharan Africa (SSA). According to WHO, the 
HBV/HIV co-infected rate in SSA is highest in West Africa (74%) and 
decreases in SSA countries in eastern Africa (48%) and in southern 
Africa (41%), with an average exposure rate of 44% in SSA.[50] 
Co-infected HBV/HIV individuals have a higher mortality and 
morbidity compared with individuals who are mono-infected with 
either HIV or HBV. The progression of chronic HBV to cirrhosis, end-
stage liver disease (ESLD), and HCC is more rapid in HIV-positive 
individuals than those with HBV alone.[51] Immunosupression due to 
HIV infection causes loss of anti-HBs and leads to HBV reactivation. 
In addition, HBV vaccination results in a poor antibody response due 
to the immunocompromised state and negatively impacts on HIV 
outcomes,[52] with antiretroviral therapy (ART) contributing to the 
increasing mortality attributed to HBV-associated ESLD.[53] 
We investigated HBV/HIV co-infection in ART-naïve adults in 
SA[54] and Sudan. Approximately 74% had serological markers for 
chronic HBV infection and of the 298 South Africans tested, 71 (24%) 
were HBV DNA-positive. The number of lifetime sexual partners 
was the only factor differentiating HBV DNA-positive from HBV 
DNA-negative individuals, implicating sexual transmission for either 
HBV or HIV. Of the 71 who were HBV DNA-positive, 26 (9%) were 
HBsAg-positive and 45 (15%) were HBsAg-negative. Only 7% of the 
HBsAg-negative individuals were true occult infections with viral 
loads of less than 200 IU/ml[55] and the remaining 93% had higher 
viral loads defined as HBsAg-covert.[54] The individuals who were 
HBsAg-negative did not differ significantly from the HBsAg-positive 
in terms of viral load and CD4 counts. HIV-infected individuals were 
predominantly infected with HBV subgenotype A1.[16] We identified 
mutations that could account for both the HBeAg- and HBsAg-
negativity. HBV isolates from HIV-infected individuals had pre-S 
deletion mutants that were identical to those isolated from HCC 
patients. In a study we carried out in collaboration with Chinese 
colleagues, we showed that 1762T1764A or pre-S deletions occurred 
more frequently (44.3% and 23%, respectively) in isolates from HBV/
HIV co-infected compared with HBV mono-infected individuals 
(21.3% and 4.9%, respectively) (χ2=7.290, p<0.05; χ2=8.270, p<0.05). 
In the SA study, 10% of patients had drug resistance mutations prior 
to the initiation of ART.[16]
In the Sudanese study 358 HIV-infected individuals were tested: 96 
(63%) had exposure to HBV and 27% were HBV DNA-positive. Risk 
factors for HBV DNA-positivity included a previous history of blood 
transfusions, dental procedures, jaundice and WHO classification of 
AIDS of 3 to 4.[56] Of the 96 HBV DNA-positive individuals, 42 were 
HBsAg-positive (11.7%) and 54 HBsAg-negative (15.1%), with higher 
viral loads in the HBsAg-positive individuals. A higher proportion 
of the HBsAg-negative individuals (65%) were true HBsAg-occult 
and the remaining 35% were HBsAg-covert[56] which contrasts with 
the SA study described above.[54] The course of HBV and/or HIV 
infection and in genotypes (subgenotype D and E v. subgenotype A1) 
may contribute to these differences. Compared with HBV mono-
infected individuals, the frequency of subgenotype D/E recombinant 
and subgenotype A was higher in HBV/HIV co-infected Sudanese, 
as was the intragroup divergence of genotype E.[22] Isolates from two 
patients infected with genotype E revealed pre-S deletion mutants, 
which were similar to those seen in HIV-co-infected patients from 
SA and from patients with HCC.
In both the South African and Sudanese studies, we found that 
approximately 25% of HIV-infected individuals were co-infected 
with HBV and 15% were HBsAg-negative. Therefore HBsAg 
serological testing under-estimates the presence of HBV in HIV 
co-infected individuals. In the case of the South Africans infected 
predominantly with subgenotype A1, the HBsAg-covert infections 
did not differ from overt infections in terms of viral load. HBV 
from HIV co-infected individuals from both cohorts had pre-S 
deletion mutants identical to those isolated from HCC patients. 
Drug resistance mutations in HBV isolates can occur prior to the 
initation of ART. 
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Conclusions
Strains of HBV commonly found in Africa differ from those outside 
Africa both in terms of molecular and functional characteristics 
and therefore studies conducted outside Africa cannot necessarily 
be extrapolated to the African continent. Although considerable 
progress has been made in Africa with regard to HBV genotyping 
research, there is no room for complacency. Unprecedented human 
migrations, currently taking place from Africa, are contributing to 
the dispersion of HBV from a continent where HBV is endemic to 
low endemicity areas. Introduction of the virus to regions of the 
world where universal vaccination is not generally practised will 
hamper efforts to achieve the WHO target of global eradication of 
HBV as a public health threat by 2030. 
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